Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Biosimilars: Regulatory Issues' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Biosimilars: Regulatory Issues Europe continues to make strides while the US lags behind |
December 2006 | £2005 | 100 % |
|
Global Generics Guide: Part 2 Benchmarking country markets and strategic issue |
June 2006 | £8695 | 43.5 % |
|
When Patients Become Plaintiffs A Primer on Drug and Medical Device Liability |
January 2006 | £1095 | 33.5 % |
|
World Generic Market Report 2007 |
November 2006 | £595 | 33 % |
|
Future of Biosimilars, The Key opportunities & emerging therapies |
August 2007 | £1495 | 32.2 % |
|
Quality for Biologics Critical quality attributes, process and change control, product variation, characterisation, and regulatory concerns |
December 2008 | £1495 | 32 % |
|
Consolidation in the Generic Pharmaceutical Industry An evolving landscape |
October 2007 | £1250 | 30 % |
|
Biogenerics, The World Market Biosimilars and Follow-On Biologics at a Crossroads |
April 2008 | £2135 | 27.5 % |
|
Negotiating The Emerging Biosimilars Landscape Key Developments in The Regulatory Environment |
February 2009 | £2025 | 23.45 % |
|
Commercial Perspectives: Drug Treatment in End-Stage Renal Disease The Price of Failure |
January 2006 | £4350 | 22.5 % |
|
Biosimilars Evolution or Revolution |
September 2006 | £1950 | 22.4 % |
|
A Guide to Biosimilars, Biogenerics and Follow-on Biologics |
January 2007 | £1095 | 19.95 % |
|
Biosimilars: a viable market? |
September 2008 | £1295 | 17.85 % |
|
Teva Pharmaceutical Industries Generics Company Intelligence Report |
June 2008 | £195 | 17 % |
|
Pipeline/Commercial Insight: Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications |
June 2007 | £7600 | 16.5 % |
|
Biosimilars and Follow-On Biologics Report The Global Outlook 2009-2024 |
April 2009 | £1499 | 16.1 % |
|
Delivering New Biopharmaceutical Therapies Challenges & Opportunities |
January 2009 | £945 | 16.1 % |
|
Drug Approval Trends at the FDA and EMEA Process Improvements, Heightened Scrutiny and Industry Response |
April 2008 | £1995 | 15.75 % |
|
Generic Series: An Introduction to the Canadian Generics Market Key trends and leading companies shaping the market |
June 2007 | £2005 | 13.65 % |
|
Pricing and Reimbursement Risk and Opportunity in Pharmaceutical Deal Making |
May 2007 | £1695 | 11.55 % |
|
New Dynamics and Challenges in The Generics Market 2007 |
January 2007 | £1870 | 11.2 % |
|
Pharmaceutical Regulatory Affairs in The Eu & US |
January 2006 | £1095 | 11.2 % |
|
Global Biotech Market Analysis and Forecasts, 2008-2023 |
August 2008 | £1499 | 9.45 % |
|
Pharmaceutical Regulatory Affairs in the EU and US |
December 2006 | £1095 | 9.1 % |
|
The Pharmaceutical Industry 2008 Current and Future Trends and Strategic Issues Shaping Pharma |
March 2008 | £3010 | 8.75 % |
|
Commercial and Pipeline Insight: Inflammatory Bowel Disease Competition Increases for the Biologics |
November 2006 | £6000 | 8.05 % |
|
Global Clinical Trial Business Report & Analysis 2008-2018 |
July 2008 | £1499 | 7.7 % |
|
Commercial Insight Top 20 Cancer Therapeutics |
July 2006 | £8695 | 7 % |
|
Commercial Insight: Cardiovascular market overview Raft of patent expires threaten blockbusters |
October 2007 | £7600 | 6.65 % |
|
Biomanufacturing Strategies Market Drivers, Build-Vs-Buy Decisions And Opportunities In Contract Relationship Management |
September 2007 | £1495 | 6.3 % |
|
Forecast Insight: Multiple Sclerosis Tysabri to prevail despite safety setbacks |
August 2008 | £7600 | 6.3 % |
|
World Generics Market 2006-2011; The |
May 2006 | £1499 | 5.95 % |
|
Monoclonal Antibodies in Cancer Therapy 2009-2024 |
May 2009 | £1499 | 5.6 % |
|
World Generic Market Report 2009 |
January 2009 | £595 | 4.55 % |
